BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 29455885)

  • 1. Vincristine resistance in relapsed neuroblastoma can be efficiently overcome by Smac mimetic LCL161 treatment.
    Frommann K; Appl B; Hundsdoerfer P; Reinshagen K; Eschenburg G
    J Pediatr Surg; 2018 Oct; 53(10):2059-2064. PubMed ID: 29455885
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modulation of Respiration and Mitochondrial Dynamics by SMAC-Mimetics for Combination Therapy in Chemoresistant Cancer.
    Hagenbuchner J; Oberacher H; Arnhard K; Kiechl-Kohlendorfer U; Ausserlechner MJ
    Theranostics; 2019; 9(17):4909-4922. PubMed ID: 31410190
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of Smac mimetics as novel substrates for p-glycoprotein.
    Hugle M; Czaplinski S; Habermann K; Vogler M; Fulda S
    Cancer Lett; 2019 Jan; 440-441():126-134. PubMed ID: 30312727
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential role of RIP1 in Smac mimetic-mediated chemosensitization of neuroblastoma cells.
    Czaplinski S; Abhari BA; Torkov A; Seggewiß D; Hugle M; Fulda S
    Oncotarget; 2015 Dec; 6(39):41522-34. PubMed ID: 26575016
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sensitization of neuroblastoma for vincristine-induced apoptosis by Smac mimetic LCL161 is attended by G2 cell cycle arrest but is independent of NFκB, RIP1 and TNF-α.
    Langemann D; Trochimiuk M; Appl B; Hundsdoerfer P; Reinshagen K; Eschenburg G
    Oncotarget; 2017 Oct; 8(50):87763-87772. PubMed ID: 29152118
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Smac mimetic LCL161 supports neuroblastoma chemotherapy in a drug class-dependent manner and synergistically interacts with ALK inhibitor TAE684 in cells with ALK mutation F1174L.
    Najem S; Langemann D; Appl B; Trochimiuk M; Hundsdoerfer P; Reinshagen K; Eschenburg G
    Oncotarget; 2016 Nov; 7(45):72634-72653. PubMed ID: 27655666
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Smac mimetic LCL161 overcomes protective ER stress induced by obatoclax, synergistically causing cell death in multiple myeloma.
    Ramakrishnan V; Gomez M; Prasad V; Kimlinger T; Painuly U; Mukhopadhyay B; Haug J; Bi L; Rajkumar SV; Kumar S
    Oncotarget; 2016 Aug; 7(35):56253-56265. PubMed ID: 27494845
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Smac mimetics LCL161 and GDC-0152 inhibit osteosarcoma growth and metastasis in mice.
    Shekhar TM; Burvenich IJG; Harris MA; Rigopoulos A; Zanker D; Spurling A; Parker BS; Walkley CR; Scott AM; Hawkins CJ
    BMC Cancer; 2019 Sep; 19(1):924. PubMed ID: 31521127
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The IAP Protein Family, SMAC Mimetics and Cancer Treatment.
    Philchenkov A; Miura K
    Crit Rev Oncog; 2016; 21(3-4):185-202. PubMed ID: 27915971
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Smac mimetic LBW242 sensitizes XIAP-overexpressing neuroblastoma cells for TNF-α-independent apoptosis.
    Eschenburg G; Eggert A; Schramm A; Lode HN; Hundsdoerfer P
    Cancer Res; 2012 May; 72(10):2645-56. PubMed ID: 22491673
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting inhibitors of apoptosis in oral squamous cell carcinoma in vitro.
    Scheurer MJJ; Seher A; Steinacker V; Linz C; Hartmann S; Kübler AC; Müller-Richter UDA; Brands RC
    J Craniomaxillofac Surg; 2019 Oct; 47(10):1589-1599. PubMed ID: 31387829
    [TBL] [Abstract][Full Text] [Related]  

  • 12. LCL161 increases paclitaxel-induced apoptosis by degrading cIAP1 and cIAP2 in NSCLC.
    Yang C; Wang H; Zhang B; Chen Y; Zhang Y; Sun X; Xiao G; Nan K; Ren H; Qin S
    J Exp Clin Cancer Res; 2016 Sep; 35(1):158. PubMed ID: 27737687
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytotoxic effects of SMAC-mimetic compound LCL161 in head and neck cancer cell lines.
    Brands RC; Herbst F; Hartmann S; Seher A; Linz C; Kübler AC; Müller-Richter UDA
    Clin Oral Investig; 2016 Dec; 20(9):2325-2332. PubMed ID: 26846923
    [TBL] [Abstract][Full Text] [Related]  

  • 14. IAP antagonists Birinapant and AT-406 efficiently synergise with either TRAIL, BRAF, or BCL-2 inhibitors to sensitise BRAFV600E colorectal tumour cells to apoptosis.
    Perimenis P; Galaris A; Voulgari A; Prassa M; Pintzas A
    BMC Cancer; 2016 Aug; 16():624. PubMed ID: 27520705
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A small molecule Smac-mimic compound induces apoptosis and sensitizes TRAIL- and etoposide-induced apoptosis in breast cancer cells.
    Bockbrader KM; Tan M; Sun Y
    Oncogene; 2005 Nov; 24(49):7381-8. PubMed ID: 16044155
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Proteomic Level Changes on Treatment in MCF-7/DDP Breast Cancer Drug- Resistant Cells.
    Jin G; Wang K; Liu Y; Liu X; Zhang X; Zhang H
    Anticancer Agents Med Chem; 2020; 20(6):687-699. PubMed ID: 32053082
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Blockade of Inhibitors of Apoptosis Proteins in Combination with Conventional Chemotherapy Leads to Synergistic Antitumor Activity in Medulloblastoma and Cancer Stem-Like Cells.
    Chen SM; Li YY; Tu CH; Salazar N; Tseng YY; Huang SF; Hsieh LL; Lui TN
    PLoS One; 2016; 11(8):e0161299. PubMed ID: 27537345
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Smac mimetic Birinapant induces apoptosis and enhances TRAIL potency in inflammatory breast cancer cells in an IAP-dependent and TNF-α-independent mechanism.
    Allensworth JL; Sauer SJ; Lyerly HK; Morse MA; Devi GR
    Breast Cancer Res Treat; 2013 Jan; 137(2):359-71. PubMed ID: 23225169
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SapC-DOPS nanovesicles induce Smac- and Bax-dependent apoptosis through mitochondrial activation in neuroblastomas.
    Sulaiman MK; Chu Z; Blanco VM; Vallabhapurapu SD; Franco RS; Qi X
    Mol Cancer; 2015 Apr; 14():78. PubMed ID: 25889084
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reactivation of Smac-mediated apoptosis in chronic lymphocytic leukemia cells: mechanistic studies of Smac mimetic.
    Balakrishnan K; Fu M; Onida F; Wierda WG; Keating MJ; Gandhi V
    Oncotarget; 2016 Jun; 7(26):39458-39472. PubMed ID: 27223062
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.